Search
Methopterin
go.drugbank.com/drugs/DB16620InvestigationalMethopterin is thought to have effects on osteoclasts and to inhibit inflammatory bone destruction.[A229843]
Calcium Phosphate
go.drugbank.com/drugs/DB11348ApprovedInvestigationalCalcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] .
SCB-2019
go.drugbank.com/drugs/DB15805InvestigationalThe vaccine was developed and tested by Clover Biopharmaceuticals AUS Pty Ltd.. … As of June 2020, the company is pursuing a randomized, double blind, placebo controlled study (NCT04405908) to test the safety and immunogenicity of the vaccine.
Iroxanadine
go.drugbank.com/drugs/DB05444ExperimentalBRX-235 (iroxanadine) is a a novel small molecule synthesized by Biorex, Hungary that acts as a cardioprotective agent. … BRX-235 also causes translocation of calcium-dependent protein kinase C isoform to membranes.
Brilaroxazine
go.drugbank.com/drugs/DB09226InvestigationalBrilaroxazine (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder. … Reviva Pharmaceuticals also intends to investigate RP5063 for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease
FINLAY-FR-1
go.drugbank.com/drugs/DB16524ExperimentalFINLAY-FR-1, also known as Soberana 01, is a vaccine candidate for COVID-19 that is being led developmentally by the Finlay Vaccine Institute[L31373]. … It is currently being tested in the clinical trial RPCEC00000332 (Phase I / II, randomized, controlled, adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and immunogenicity
Siagoside
go.drugbank.com/drugs/DB12351InvestigationalTreatment results in a 52% decrease in mortality 48 hours after the induction of ischemia in gerbils by permanent unilateral ligation of the common carotid artery. … Sygen appears to be beneficial in patients with severe spinal cord injury.
XL784
go.drugbank.com/drugs/DB04991InvestigationalIt is being developed by Exelixis, Inc. … Results of single dose Phase I clinical trials of XL784 administered orally to 96 healthy volunteers have demonstrated that XL784 has attractive safety and pharmacokinetic profiles.
MVA-BN-brachyury-TRICOM vaccine
go.drugbank.com/drugs/DB17424Investigational[L44513] MVA-BN-brachyury-TRICOM vaccine is administered as a priming vaccine, followed by the administration of the fowlpox virus(FPV)‐Brachyury booster vaccine. … These immune-enhancing co-stimulatory molecules exert immunostimulatory and antineoplastic actions.
OT-551
go.drugbank.com/drugs/DB05650Investigationaldegeneration (AMD) by protecting against retina photoreceptor cell death and inhibiting angiogenesis, the growth of small blood vessels leading to the wet-form of AMD. … OT-551 is a novel small molecule that is topically dosed in an eye drop and has the unique ability to penetrate cell membranes and reach both the front and the back of the eye.